(Q34207135)

31 July 2017

1 reference

title

Lovastatin and beyond: the history of the HMG-CoA reductase inhibitors (English)

1 reference

31 July 2017

Jonathan A Tobert

1

1 reference

31 July 2017

1 July 2003

1 reference

Nature Reviews Drug Discovery

31 July 2017

1 reference

31 July 2017

2

1 reference

31 July 2017

517-526

1 reference

31 July 2017

7

1 reference

https://scigraph.springernature.com/pub.10.1038/nrd1112

31 July 2017

0 references

cites work

Preventing coronary artery disease by lowering cholesterol levels: fifty years from bench to bedside

1 reference

Clinical misconceptions dispelled by epidemiological research

31 March 2020

1 reference

The seven countries study: 2,289 deaths in 15 years

31 March 2020

1 reference

ML-236A, ML-236B, and ML-236C, new inhibitors of cholesterogenesis produced by Penicillium citrinium

31 March 2020

1 reference

Inhibition of cholesterol synthesis in vitro and in vivo by ML-236A and ML-236B, competitive inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A reductase

31 March 2020

1 reference

Hypolipidemic effects of CS-500 (ML-236B) in WHHL-rabbit, a heritable animal model for hyperlipidemia

31 March 2020

1 reference

Hypolipidemic effects in monkeys of ML-236B, a competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase

31 March 2020

1 reference

Hypolipidemic effects in dogs of ML-236B, a competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme a reductase

31 March 2020

1 reference

The effect of compactin, a potent inhibitor of 3-hydroxy-3-methylglutaryl coenzyme-A reductase activity, on cholesterogenesis and serum cholesterol levels in rats and chicks

31 March 2020

1 reference

Lovastatin, an inhibitor of cholesterol synthesis, induces hydroxymethylglutaryl-coenzyme A reductase directly on membranes of expanded smooth endoplasmic reticulum in rat hepatocytes

31 March 2020

1 reference

Hepatic responses to inhibition of 3-hydroxy-3-methylglutaryl-CoA reductase: a comparison of atorvastatin and simvastatin

31 March 2020

1 reference

Mevinolin: a highly potent competitive inhibitor of hydroxymethylglutaryl-coenzyme A reductase and a cholesterol-lowering agent

31 March 2020

1 reference

Effect of an inhibitor of 3-hydroxy-3-methyglutaryl coenzyme A reductase on serum lipoproteins and ubiquinone-10-levels in patients with familial hypercholesterolemia

31 March 2020

1 reference

Reduction of serum cholesterol in heterozygous patients with familial hypercholesterolemia. Additive effects of compactin and cholestyramine

31 March 2020

1 reference

Rapid and substantial lowering of human serum cholesterol by mevinolin (MK-803), an inhibitor of hydroxymethylglutaryl-coenzyme A reductase

31 March 2020

1 reference

Cholesterol-lowering effect of mevinolin, an inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme a reductase, in healthy volunteers

31 March 2020

1 reference

Mevinolin and colestipol stimulate receptor-mediated clearance of low density lipoprotein from plasma in familial hypercholesterolemia heterozygotes

31 March 2020

1 reference

Hypocholesterolemic effects of mevinolin in patients with heterozygous familial hypercholesterolemia

31 March 2020

1 reference

Lovastatin (mevinolin) in the treatment of heterozygous familial hypercholesterolemia. A multicenter study

31 March 2020

1 reference

Therapeutic response to lovastatin (mevinolin) in nonfamilial hypercholesterolemia. A multicenter study. The Lovastatin Study Group II

31 March 2020

1 reference

A multicenter comparison of lovastatin and probucol for treatment of severe primary hypercholesterolemia. The Lovastatin Study Group IV

31 March 2020

1 reference

Systematic review of dietary intervention trials to lower blood total cholesterol in free-living subjects

31 March 2020

1 reference

Animal safety and toxicology of simvastatin and related hydroxy-methylglutaryl-coenzyme A reductase inhibitors

31 March 2020

1 reference

Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study

31 March 2020

1 reference

Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)

31 March 2020

1 reference

Safety and tolerability of cholesterol lowering with simvastatin during 5 years in the Scandinavian Simvastatin Survival Study

31 March 2020

1 reference

MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial

31 March 2020

1 reference

Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group

31 March 2020

1 reference

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators

31 March 2020

1 reference

Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial

31 March 2020

1 reference

Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre ra

31 March 2020

1 reference

Lovastatin and the human lens; results of a two year study. The MSDRL Study Group

31 March 2020

1 reference

Absence of effect of simvastatin on the progression of lens opacities in a randomised placebo controlled study. Oxford Cholesterol Study Group.

31 March 2020

1 reference

Ocular drug safety and HMG-CoA-reductase inhibitors

31 March 2020

1 reference

Expanded clinical evaluation of lovastatin (EXCEL) study results. II. Assessment of the human lens after 48 weeks of treatment with lovastatin

31 March 2020

1 reference

31 March 2020

The liver and lovastatin

1 reference

Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials

31 March 2020

1 reference

Follow-up study of patients randomized in the Scandinavian simvastatin survival study (4S) of cholesterol lowering

31 March 2020

1 reference

Central nervous system effects of HMG CoA reductase inhibitors: lovastatin and pravastatin on sleep and cognitive performance in patients with hypercholesterolemia.

31 March 2020

1 reference

Comparison of effects on sleep of lovastatin and pravastatin in hypercholesterolemia.

31 March 2020

1 reference

Do cholesterol-lowering agents affect brain activity? A comparison of simvastatin, pravastatin, and placebo in healthy volunteers

31 March 2020

1 reference

Effects of treatment with lovastatin and pravastatin on daytime cognitive performance.

31 March 2020

1 reference

Randomised placebo controlled trial of effect on mood of lowering cholesterol concentration. Oxford Cholesterol Study Group

31 March 2020

1 reference

Myolysis and acute renal failure in a heart-transplant recipient receiving lovastatin

31 March 2020

1 reference

Concomitant use of cytochrome P450 3A4 inhibitors and simvastatin

31 March 2020

1 reference

Risk for myopathy with statin therapy in high-risk patients.

31 March 2020

1 reference

A receptor-mediated pathway for cholesterol homeostasis

31 March 2020

1 reference

Plasma mevalonic acid, an index of cholesterol synthesis in vivo, and responsiveness to HMG-CoA reductase inhibitors in familial hypercholesterolaemia.

31 March 2020

1 reference

Regulation of cholesterol synthesis in rat adrenal gland through coordinate control of 3-hydroxy-3-methylglutaryl coenzyme A synthase and reductase activities

31 March 2020

1 reference

Regulatory role for hepatic low density lipoprotein receptors in vivo in the dog

31 March 2020

1 reference

Mevinolin, an inhibitor of cholesterol synthesis, induces mRNA for low density lipoprotein receptor in livers of hamsters and rabbits

31 March 2020

1 reference

Influence of pravastatin, a specific inhibitor of HMG-CoA reductase, on hepatic metabolism of cholesterol.

31 March 2020

1 reference

Effects of lovastatin therapy on very-low-density lipoprotein triglyceride metabolism in subjects with combined hyperlipidemia: evidence for reduced assembly and secretion of triglyceride-rich lipoproteins

31 March 2020

1 reference

Expanded-dose simvastatin is effective in homozygous familial hypercholesterolaemia

31 March 2020

1 reference

The cholesterol controversy is over. Why did it take so long?

31 March 2020

1 reference

Lowering cholesterol concentrations and mortality: a quantitative review of primary prevention trials

31 March 2020

1 reference

Should there be a moratorium on the use of cholesterol lowering drugs?

31 March 2020

1 reference

Prevention of coronary heart disease in clinical practice. Recommendations of the Task Force of the European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertension

31 March 2020

1 reference

Coronary angiographic changes with lovastatin therapy. The Monitored Atherosclerosis Regression Study (MARS).

31 March 2020

1 reference

Effects of monotherapy with an HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography. The Canadian Coronary Atherosclerosis Intervention Trial.

31 March 2020

1 reference

Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The Regression Growth Evaluation Statin Study (REGRESS)

31 March 2020

1 reference

Pravastatin limitation of atherosclerosis in the coronary arteries (PLAC I): reduction in atherosclerosis progression and clinical events. PLAC I investigation

31 March 2020

1 reference

Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Asymptomatic Carotid Artery Progression Study (ACAPS) Research Group

31 March 2020

1 reference

Kuopio Atherosclerosis Prevention Study (KAPS). A population-based primary preventive trial of the effect of LDL lowering on atherosclerotic progression in carotid and femoral arteries.

31 March 2020

1 reference

Serum cholesterol--the knave of hearts and the joker

31 March 2020

1 reference

Is cholesterol reduction always safe?

31 March 2020

1 reference

Lower patients' cholesterol now

31 March 2020

1 reference

Reliable assessment of the effects of treatment on mortality and major morbidity, I: clinical trials

31 March 2020

1 reference

Pleiotropic effects of statins and their clinical significance

31 March 2020

1 reference

Effect of Cholesterol-Lowering Therapy on Coronary Endothelial Vasomotor Function in Patients With Coronary Artery Disease

31 March 2020

1 reference

Gemfibrozil greatly increases plasma concentrations of cerivastatin

31 March 2020

1 reference

Cerivastatin in primary hyperlipidemia: a multicenter analysis of efficacy and safety

31 March 2020

1 reference

Two decades of progress in preventing vascular disease

31 March 2020

1 reference

Statin trials in progress: unanswered questions

31 March 2020

1 reference

New lipid-modifying therapies

31 March 2020

1 reference

31 March 2020

Identifiers

DOI

10.1038/NRD1112

1 reference

PubMed ID

12815379

Dimensions Publication ID

31 July 2017

0 references

1 reference

PubMed ID

12815379